

WODA combining forces to reach patients with rare diseases across globe

13 May 2022 | News

WODA covers 68 countries on 4 continents.



EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC, and Vector Pharma, announced the newly formed World Orphan Drug Alliance (WODA). WODA aims to provide comprehensive support to pharmaceutical and biotech companies with rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patient programs through to full commercialization.

By bringing together experts for rare diseases, WODA has capabilities to provide all the services necessary for orphan medicines to reach patients in need, replacing local branches of global distributors or multinational companies.

In total, WODA covers 68 countries in the following regions: Turkey, Middle East and North Africa, Russia and CIS region, Central and Eastern Europe, Latin America and Switzerland.

About Founding Partners:

- **EffRx Pharmaceuticals** is a Switzerland based company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications.
- **Medis** based in Slovenia is the commercialization partner of choice for innovative pharmaceutical and biotech companies seeking strong business growth in Central and Eastern Europe.
- **Orpharm** is a Moscow based full-service distributor covering Russia and the Commonwealth of Independent States (CIS).
- **OrphanDC** based in Sao Paulo, Brazil acts as a partner for biotech companies in Latin America. They focus on supporting their clients from the clinical development stage throughout the product lifecycle.
- **Vector Pharma** is a Dubai based full-service distributor covering Middle East, North Africa and Turkey.